Clinical · Humanistic · Economic
Evidence that justifies value and drives access
Payers do not reimburse drugs. Instead, they reimburse outcomes relative to a documented problem. In rare disease, that documented problem is the burden of illness — and if your dossier cannot quantify it in clinical, humanistic, and economic terms, your value argument begins with a gap.
Therefore, MedPanel designs and executes rare disease burden of illness studies that generate the evidence base sponsors need to support HTA submissions, payer negotiations, label development, and publication strategy. With more than 20 years of experience, an IRB-ready recruitment infrastructure, and a verified panel spanning more than 40 countries, MedPanel produces burden evidence that meets the evidentiary standards of the most demanding regulatory and market access environments.
Clinical · Humanistic · Economic
Surveys · Diaries · Interviews · RWD
Report · Dossier · Publication · KOL
Verified panel coverage
What a Burden of Illness Study Actually Measures
Burden of illness is not a single metric. On the contrary, it is a structured evidence framework spanning three interrelated domains — clinical, humanistic, and economic burden — each of which must be measured with methods appropriate to rare disease populations, where standard epidemiological tools frequently underperform.
Clinical burden
Clinical burden captures the disease’s direct impact on patient health: symptom frequency and severity, rate of disease progression, complication incidence, hospitalisation rates, and mortality. Notably, in rare disease this data is often incomplete or fragmented across specialist centres. Therefore, primary research is a necessity rather than a supplement to secondary sources.
Humanistic burden
Humanistic burden quantifies the impact of the condition on patients’ and caregivers’ quality of life, functional capacity, and psychological wellbeing. Increasingly, this domain is central to HTA decisions in rare disease, where clinical endpoints alone may not capture the full scope of what patients experience. Specifically, PRO instruments, validated disease-specific scales, and caregiver burden assessments are the primary tools in this domain.
Economic burden
Economic burden encompasses direct medical costs — drug acquisition, hospitalisation, specialist consultations, diagnostic workup, medical devices — alongside indirect costs: productivity loss, early retirement, informal caregiving time, and out-of-pocket expenditure borne by patients and families. Moreover, for rare conditions with high unmet need and long diagnostic odysseys, the lifetime economic burden can substantially exceed what claims data alone captures.
A well-constructed rare disease burden of illness study integrates findings across all three domains into a unified evidence package. As a result, it maps directly to the value story your commercial and HEOR teams need to tell. For deeper context, see our HEOR and health economics research and rare disease research overview.
Building a Robust Evidence Base in Small Populations
The methodological challenge of rare disease burden research is not complexity — it is scale. Specifically, patient populations are small, geographically dispersed, and frequently underrepresented in existing claims databases and electronic health records. Consequently, primary research is almost always required, and the methods must be calibrated to produce statistically defensible findings from limited sample sizes.
Accordingly, MedPanel deploys a multimodal data collection approach for rare disease burden of illness studies.
- Patient and caregiver surveys are the primary instrument for humanistic and economic burden quantification. Administered via validated instruments — EQ-5D, condition-specific PRO scales, WPAI questionnaires, and bespoke caregiver burden measures — surveys run through MedPanel’s IRB-ready recruitment infrastructure. Notably, participants are recruited through verified disease registries, advocacy partnerships, and specialist clinic networks, not general consumer panels, ensuring condition confirmation before a single response is collected.
- Longitudinal patient diaries capture burden data that cross-sectional surveys miss: symptom variability over time, acute episode frequency, care utilisation patterns, and caregiver time commitment by day and task type. Moreover, diary protocols are designed for the specific cognitive and physical profile of the patient population, with digital and paper formats available.
- In-depth qualitative interviews with patients, caregivers, and treating physicians provide the contextual depth that quantitative instruments cannot generate alone. For example, these interviews surface burden dimensions not yet captured by existing PRO tools — a frequent requirement in ultra-rare conditions where validated instruments simply do not exist.
- Claims data and real-world data triangulation supplements primary research with retrospective utilisation data where available. As a result, it enables direct cost estimation and healthcare resource use (HCRU) modelling that meets payer standards for economic burden documentation.
For related capability, see our rare disease patient recruitment, caregiver studies, and HEOR and health economics research.
Time Horizon and Patient Population Segmentation
Two design decisions shape the strategic utility of a rare disease burden of illness study more than any other: the time horizon over which burden is measured, and the patient population segments across which it is disaggregated.
Time horizon
Time horizon determines whether the study captures burden at a point in time or tracks how it evolves with disease progression. For instance, cross-sectional designs are appropriate when the objective is a baseline burden snapshot for early payer engagement or HTA preparation. By contrast, longitudinal designs — structured around a defined observation period with repeated measurement — are required when the objective is modelling disease trajectory, demonstrating disease modification, or capturing how burden shifts before and after treatment initiation. Notably, MedPanel designs both, with selection driven by the sponsor’s regulatory timeline and market access strategy.
Patient population segmentation
Segmentation ensures that burden findings reflect the heterogeneity that characterises most rare conditions. Specifically, variables commonly applied include disease severity stage, genotypic or phenotypic subtype, age of onset, time since diagnosis, treatment status, and geography. Furthermore, for paediatric rare diseases, parallel caregiver burden measurement is structured as a distinct but integrated study component, capturing the full household impact of a condition that affects a child.
Importantly, segmentation decisions are made during protocol development in close collaboration with the sponsor’s medical affairs and HEOR teams, with input from clinical advisors where the framework requires clinical validation. For more, see our caregiver studies and rare disease research overview.
From Burden Report to Publication-Ready Analysis
A rare disease burden of illness study is an investment in a body of evidence, not a single deliverable. Therefore, MedPanel structures study outputs to serve multiple downstream uses simultaneously, so the same primary data generates value across medical affairs, market access, and publication strategy.
- Burden of illness report. The primary deliverable — a comprehensive, sponsor-ready document presenting methodology, validated instruments, sample characteristics, and findings across all three burden domains. Specifically, it is structured to support internal review, medical affairs briefing, and external presentation to payers and HTA bodies.
- Payer dossier inputs. Burden data formatted to meet the evidence requirements of AMCP dossiers, NICE technology appraisal submissions, HAS dossiers, and equivalent HTA formats. In addition, it includes cost inputs for budget impact modelling, HCRU tables, and utility data where EQ-5D or condition-specific instruments were deployed.
- Publication-ready analysis. For sponsors with a publication strategy, MedPanel delivers a manuscript-ready analysis with full methodology documentation, statistical output tables, and a results narrative aligned to target journal standards. Indeed, MedPanel’s seven peer-reviewed publications reflect an established record of translating primary burden research into the literature.
- Advisory board and KOL validation. Burden findings can be routed through a rare disease virtual advisory board for expert validation before submission or publication. As a result, the evidentiary chain is strengthened, surfacing clinical nuance that quantitative analysis alone may not capture.
For related capability, see our HEOR and health economics research, rare disease virtual advisory boards, and rare disease research overview.
Why Burden Research Demands a Specialist Partner
Rare disease burden of illness studies fail in predictable ways when executed by general market research vendors: patient samples that are not condition-confirmed, PRO instruments not validated for the target population, time horizons that do not align with payer submission requirements, and analysis that cannot withstand HTA scientific scrutiny. Importantly, these failures are not recoverable once a submission window has closed.
By contrast, MedPanel was built for this research environment. Specifically, our patient recruitment is verified and IRB-ready, our physician panel is credentialed rather than self-reported, and our HEOR and outcomes research team has rare disease as a primary — not incidental — competency. Moreover, our global reach extends to the low-prevalence geographies and specialist centres where rare disease burden evidence is generated and validated.
For sponsors preparing for launch, HTA submission, or label expansion in a rare condition, a MedPanel burden of illness study therefore provides the evidence foundation that makes every downstream access conversation easier to have and harder to dismiss. For more, see our rare disease patient recruitment and physician recruitment and engagement research.
Design a study
Design a Rare Disease Burden of Illness Study
The right burden evidence, built to the right standard, changes the access conversation. Accordingly, MedPanel’s rare disease outcomes research team will work with your HEOR, medical affairs, and market access colleagues to design a study that answers the questions your payers will ask — before they ask them.
Clinical, humanistic & economic evidence
Multimodal, condition-confirmed data collection
Dossier-, publication-, and KOL-ready outputs
Built to HTA and payer evidentiary standards
Share your condition area, your target submission markets, and your timeline. We will outline a burden study design built to deliver.